Bär & Karrer Advises Essex Woodlands Health Ventures Funds and Other Investors on the Sale of a Large Minority Stake in Molecular Partners
Essex Woodlands Health Ventures Funds, Index Ventures Funds, Johnson & Johnson Innovation and other long-term venture capital investors (the Selling Shareholders) reduced their holding by way of a block trade transaction in the amount of 14.36% of share capital in the Swiss listed Molecuar Partners AG, a biopharmaceutical company. Private investors acquired the shares from the Selling Shareholders in secondary block trades.
Bär & Karrer acted as legal advisor to the Selling Shareholders. The team included Thomas U. Reutter, Till Spillmann, Rebecca Schori and Daniel Raun (all Capital Markets).